Neogenomics (NEO) Free Cash Flow Growth (1y) (2011 - 2026)
Neogenomics (NEO) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 51.58% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 16.06% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 112.68% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 87.85% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 23.29% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -20.33% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | -21.08% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 33.01% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 5.28% |
| 10 | Neogenomics | 2.05 Bn | 1.90 Bn | 91.88 Mn | -16.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.18% |
| Mar 31, 2026 | 55.96% |
| Dec 31, 2025 | -262.87% |
| Sep 30, 2025 | 136.70% |
| Jun 30, 2025 | 1,620.76% |
| Mar 31, 2025 | 5.31% |
| Dec 31, 2024 | -116.77% |
| Sep 30, 2024 | 84.11% |
| Jun 30, 2024 | 109.00% |
| Mar 31, 2024 | -39.26% |
| Dec 31, 2023 | 230.51% |
| Sep 30, 2023 | 59.48% |
| Jun 30, 2023 | 66.87% |
| Mar 31, 2023 | 39.29% |
| Dec 31, 2022 | 74.12% |
| Sep 30, 2022 | -6.03% |
| Jun 30, 2022 | -20.02% |
| Mar 31, 2022 | -173.54% |
| Dec 31, 2021 | -475.42% |
| Sep 30, 2021 | -210.24% |